These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 14688010)

  • 1. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
    Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
    Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
    [No Abstract]   [Full Text] [Related]  

  • 2. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
    Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
    Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
    Doyen J; Italiano A; Peyrade F; Bouyer C; Thyss A
    Br J Haematol; 2008 May; 141(5):744-5. PubMed ID: 18373704
    [No Abstract]   [Full Text] [Related]  

  • 4. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
    Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
    Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
    Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
    Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
    Wang ES; Zeidan A; Tan W; Wilding GE; Ford LA; Wallace PK; Hahn TE; Battiwalla M; McCarthy PL; Wetzler M
    Leuk Lymphoma; 2012 Oct; 53(10):2085-8. PubMed ID: 21740302
    [No Abstract]   [Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
    Molnár I; Powell BL
    Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
    Ichikawa M; Hangaishi A; Nannya Y; Kurokawa M
    Int J Hematol; 2010 Nov; 92(4):673-4. PubMed ID: 20978876
    [No Abstract]   [Full Text] [Related]  

  • 12. [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
    Hirayama Y; Terui T; Koike K; Neda H; Ishitani K; Kohda K; Kuroda H; Iyama S; Sato T; Kobune M; Takimoto R; Kato J
    Rinsho Ketsueki; 2009 Aug; 50(8):663-5. PubMed ID: 19915382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab ozogamicin: time to resurrect?
    Ravandi F; Estey EH; Appelbaum FR; Lo-Coco F; Schiffer CA; Larson RA; Burnett AK; Kantarjian HM
    J Clin Oncol; 2012 Nov; 30(32):3921-3. PubMed ID: 22987091
    [No Abstract]   [Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
    Boyiadzis M; Redner RL; Raptis A; Hou JZ; Agha M; Foon KA
    Ann Hematol; 2011 Jun; 90(6):733-5. PubMed ID: 20857113
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
    Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
    Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
    Stone RM; Moser B; Sanford B; Schulman P; Kolitz JE; Allen S; Stock W; Galinsky I; Vij R; Marcucci G; Hurd D; Larson RA;
    Leuk Res; 2011 Mar; 35(3):329-33. PubMed ID: 20688393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.
    Bayraktar UD; Domingo GC; Schmit J; Pereira D
    Leuk Lymphoma; 2011 May; 52(5):913-5. PubMed ID: 21417821
    [No Abstract]   [Full Text] [Related]  

  • 19. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.